



Drug Quantity Management – Per Days Flurandrenolide Topical Products Duration Limit

Table of Contents

| | |
|--|---|
| National Formulary Medical Necessity | 1 |
| Conditions Not Covered..... | 2 |
| Background..... | 2 |
| References | 3 |
| Revision History..... | 3 |

Product Identifier(s)

Effective 1/1/23 to 2/6/23: 109031
Effective 2/7/23: 65505

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

Drugs Affected

- Cordran® (flurandrenolide cream 0.025% and 0.05% [generic], ointment 0.05% [generic], lotion 0.05% [generic])
- Nolix™ (flurandrenolide cream 0.05%, lotion 0.05%, generic)

Drug Quantity Limits

| Product | Package Size | Maximum Quantity per 30 Days |
|--|-------------------------------|------------------------------|
| Cordran® (flurandrenolide cream 0.025%) | 120 gram tube | 120 grams* |
| flurandrenolide cream 0.05% Cordran®, Nolix™, generics) | 60 gram tube 120 gram tube | 120 grams* |
| Flurandrenolide ointment 0.05% (Cordran®, generics) | 60 gram tube | 120 grams* |
| Flurandrenolide lotion 0.05% (Cordran®, Nolix™, generics) | 120 mL bottle | 120 mL* |

* This is enough drug to cover 8% of the body surface area when applying two times daily for 30 days.

Criteria

Cigna covers quantities as medically necessary when the following criteria are met:

All approvals are provided for 12 months in duration.

Cordran 0.025% cream

1. If an individual needs to treat greater than 8% of body surface area, approve up to 240 grams per month.
2. If an individual needs to administer the medication more frequently than two times a day, approve up to 240 grams per month.

flurandrenolide 0.05% cream (Cordran, Nolix, generic), and flurandrenolide 0.05% ointment (Cordran, generic)

1. If an individual needs to treat greater than 8% of body surface area, approve up to 180 grams per month.
2. If an individual needs to administer the medication more frequently than two times a day, approve up to 180 grams per month.

Flurandrenolide lotion (Cordran, Nolix, generic)

1. If an individual needs to treat greater than 8% of body surface area or is administering more frequently than two times a day, approve up to 240 mL per month.
2. If an individual needs to administer the medication more frequently than two times a day, approve up to 240 mL per month.

Conditions Not Covered

Any other exception is considered not medically necessary, including the following:

1. No overrides are recommended for use in compounded formulations.
2. No overrides are recommended for any for any non-FDA-approved indications.

Background

Overview

Flurandrenolide cream, lotion and ointment are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, including moderate to severe plaque psoriasis.¹⁻⁴

Moderate to severe psoriasis is typically defined as involvement of more than 5% to 10% of the body surface area or involvement of the face, palm or sole, or disease that is otherwise disabling. For reference, the entire palmar surface, including fingers, of one hand is approximately 1% percent of the body surface area. Patients with > 5% to 10% body surface area affected are generally candidates for phototherapy or systemic therapy, since application of topical agents to a large area is not usually practical or acceptable for most patients.

Dosing/Availability

Flurandrenolide cream, lotion and ointment are applied to the affected area two to three times daily.¹⁻³

Cordran 0.025% cream is supplied in 120 gram tubes.² Flurandrenolide 0.05 % cream is supplied in 60 gram and 120 gram tubes; Cordran 0.05% cream is supplied in 120 gram tubes and Nolix 0.05% cream is supplied in 60 gram tubes.^{2,3} Flurandrenolide 0.05% lotion (Cordran, Nolix, generic) is supplied in 120 gram bottles.^{1,4} Flurandrenolide 0.05% ointment (Cordran, generic) is supplied in 60 gram tubes.²

Application Information

When determining the amount of a topical corticosteroid to apply, a standard measure, the fingertip unit (FTU), is often used.⁵ One FTU is the amount of product that is squeezed out of a standard tube along an adult's fingertip. One FTU is equivalent to approximately 0.5 g and provides enough product to treat an area of skin that is twice the size of one adult hand, or approximately 2% of an adult's total body surface area (BSA). Therefore, it is assumed that 1 g of a topical corticosteroid would provide enough product for one application to approximately 4% of the patient's BSA. For children, an FTU is still the amount of product that will fit on an adult's index fingertip. The amount of BSA that the application will cover depends on the size of the child.

Based on the FTU method, the quantity limits below provide enough flurandrenolide cream, ointment, or lotion to cover approximately 8% of the patient's BSA when applying two times daily for 1 month.

References

1. Cordran Lotion, 0.05% [prescribing information]. Malvern PA: Almirall; July 2016.
2. Cordran Cream, 0.025%, 0.05%; Cordran Ointment, 0.05% [prescribing information]. Malvern PA: Almirall; May 2017.
3. Nolix Cream, 0.05% [prescribing information]. Austin, TX: Artesa Labs; August 2017.
4. Nolix Lotion, 0.05% [prescribing information]. Austin, TX: Artesa Labs; October 2017.
5. Eichenfeld LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. *J Am Acad Dermatol.* 2014;71:116-132.

Revision History

| Type of Revision | Summary of Changes | Approval Date |
|------------------|---|---------------|
| Annual Revision | Cordran 0.025% cream. Criteria were modified to approve additional quantities up to 240 grams to accommodate packaging (previously 180 grams). Flurandrenolide 0.05% lotion (Cordran, Nolix, generic). Criteria were modified to approve additional quantities up to 240 mL to accommodate packaging (previously approved as 180 grams). | 03/23/2022 |

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc. and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2023 Cigna.